Methods, substrates, and systems useful for cell seeding of medical grafts

Patent metadata

Field	Value
Publication number	US-11077231-B2
Application number	US-201514834971-A
Country	US
Kind code	B2
Filing date	Aug 25, 2015
Priority date	May 25, 2010
Publication date	Aug 3, 2021
Grant date	Aug 3, 2021

Abstract

Described are methods, cell growth substrates, and devices that are useful in preparing cell-containing graft materials for administration to patients. Tubular passages can be defined in cell growth substrates to promote distribution of cells into the substrates. Also described are methods and devices for preparing cell-seeded graft compositions, methods and devices for preconditioning cell growth substrates prior to application of cells, and cell seeded grafts having novel substrates, and uses thereof.

First claim

The invention claimed is:

1. A cell growth substrate composition, comprising:
a particulate material comprising a population of cell growth substrate particles each being a sheet having a sheet thickness of about 20 to about 2000 microns, wherein at least 25% of the substrate particles, when considered in the plane of the sheet, each have a first, maximum cross sectional dimension axis length which is no more than about two times the length of a second cross sectional axis taken on a line perpendicular to and centered upon the maximum cross sectional dimension axis, and wherein said cell growth substrate particles each comprise a membranous soft tissue with a sheet structure as isolated from a soft tissue source.

2. The substrate composition of claim 1 , wherein said cell growth substrate particles are characterized by having been cut from a larger sheet of cell growth substrate material, and wherein said cell growth substrate material is a membranous extracellular matrix tissue with a sheet structure.

3. The composition of claim 1 , wherein the maximum cross sectional axis length is in the range of about 20 microns to about 2000 microns.

4. The composition of claim 1 , also comprising cells attached to said particles.

5. The composition of claim 4 , wherein the cells cover substantially the entire outer surface of said particles.

6. The composition of claim 5 , wherein the cells form a substantially confluent monolayer covering the entire outer surface of said particles.

7. The composition of claim 6 , wherein the cells comprise endothelial cells, endothelial progenitor cells, or a mixture thereof.

8. The composition of claim 7 , wherein the cells are clonal.

9. The composition of claim 7 , wherein the cells consist of endothelial cells, endothelial progenitor cells, or a mixture thereof.

10. The composition of claim 1 , wherein said cell growth substrate particles each have a generally circular, ovoid, or polygonal shape.

11. The composition of claim 1 , wherein the maximum cross sectional dimension axis length is greater than the sheet thickness.

12. The composition of claim 1 , wherein said soft tissue source is selected from the group comprising: submucosa, renal capsule membrane, dermal collagen, dura mater, pericardium, fascia lata, serosa, peritoneum, or basement membrane.

13. A method for treating a patient, comprising:
introducing a particulate material of claim 1 .

14. An extracellular matrix composition, comprising:
a flowable particulate extracellular matrix material comprising membranous extracellular matrix particles each being a sheet, wherein said extracellular matrix particles are characterized by having been cut from a larger membranous soft tissue extracellular matrix sheet material to each have a generally circular, ovoid or polygonal shape and to each have a maximum cross sectional dimension axis length, considered in the plane of the sheet particles, in the range of about 100 to about 1500 microns, and wherein said extracellular matrix particles each have a thickness of about 20 to about 500 microns.

15. The composition of claim 14 , wherein for at least 25% of said extracellular matrix particles, the maximum cross sectional dimension axis length for each is no more than about two times the length of a second cross sectional axis taken on a line perpendicular to and centered upon the maximum cross sectional dimension axis.

16. The composition of claim 15 , wherein said extracellular matrix particles retain native growth factors from a source tissue for the larger extracellular matrix sheet material.

17. The composition of claim 14 , wherein said extracellular matrix particles retain native growth factors from a source tissue for the larger extracellular matrix sheet material.

18. The composition of claim 14 , also comprising cells attached to said particles.

19. The composition of claim 18 , wherein the cells cover substantially the entire outer surface of said particles.

20. The composition of claim 19 , wherein the cells form a substantially confluent monolayer covering the entire outer surface of said particles.

21. The composition of claim 18 , wherein the cells comprise endothelial cells, endothelial progenitor cells, or a mixture thereof.

22. The composition of claim 21 , wherein the cells are clonal.

23. The composition of claim 21 , wherein the cells consist of endothelial cells, endothelial progenitor cells, or a mixture thereof.

24. The composition of claim 14 , wherein said extracellular matrix particles each have a generally circular or ovoid shape.

25. The composition of claim 14 , wherein the maximum cross sectional dimension axis length is greater than the sheet thickness.

26. The composition of claim 14 , wherein said membranous soft tissue extracellular matrix sheet material is selected from the group comprising: submucosa, renal capsule membrane, dermal collagen, dura mater, pericardium, fascia lata, serosa, peritoneum, or basement membrane.

Assignees

• Muffin Inc
• Cook Biotech Inc

Inventors

• Hiles Michael C
• Johnson Chad E
• Fearnot Neal E
• Payne Thomas
• Jankowski Ronald

Classifications

• A61L27/24 Primary

  Collagen · CPC title

• C12N2533/54

  Collagen; Gelatin · CPC title

• A61L27/3633

  Extracellular matrix [ECM] · CPC title

• A61L27/3808

  Endothelial cells · CPC title

• A61L2430/02

  for reconstruction of bones; weight-bearing implants · CPC title